Current Studies Flyer

Join Our Research Flyer

Participate In Spark

About our Research Program

The UC Davis MIND Institute supports critical research designed to understand the causes and to develop effective diagnoses, treatments, preventions, and ultimately, cures for neurodevelopmental disorders. Advances in neuroscience, molecular biology, genetics, pharmacology and behavioral sciences are making inroads into understanding brain function. The MIND Institute draws from these and other disciplines to conduct collaborative multidisciplinary research on specific neurodevelopmental disorders, including Autism Spectrum Disorders, Down Syndrome, Fragile X Syndrome, Attention-Deficit/Hyperactivity Disorder (ADHD) and Chromosome 22q11.2 Deletion Syndrome.

The MIND Institute is uniquely positioned to take advantage of the outstanding expertise at UC Davis. The University offers robust programs in biological, environmental, medical and toxicological sciences.

The scope and impact of the Institute’s Research Program is exceptional. Studies ranging from basic biological studies to treatment trials, have lead to important contributions in such areas as synapse formation and plasticity, biomarkers research, evaluating startle responses, mouse model for autism, gene therapy of the brain, functions of the fragile X and MeCP2 genes, brain structure and the epidemiology of autism.

Highlighted Study of the Month

Children's Autism Metabolome Project (CAMP)

The study is evaluating a laboratory test to diagnose Autism Spectrum Disorder in early childhood. This study will compare two methods for diagnosing Autism Spectrum Disorder: a laboratory test performed on a blood sample and standard behavioral testing and observation by a trained Psychologist.

Who can participate: Children ages 18-48 months, with Autism Spectrum Disorder (ASD) Developmental Delay or Typical Development

Number of visits: 1-2 visits to the MIND Institute

What to expect: Study participation includes behavioral and psychological testing, a physical examination, review of medical history, urine sample collection, and a blood draw.

Study Coordinator: Ani Movsisyan, 916-703-0301 or Erika Bickel, 916-703-0281